{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:29:34Z","timestamp":1770917374804,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jval.2014.08.2668","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T18:48:09Z","timestamp":1415299689000},"page":"830-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Parents\u2019 Willingness to Pay for Biologic Treatments in Juvenile Idiopathic Arthritis"],"prefix":"10.1016","volume":"17","author":[{"given":"Heather F.","family":"Burnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy J.","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A.","family":"Regier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2014.08.2668_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0049-0172(96)80009-6","article-title":"Epidemiology of chronic arthritis in childhood","volume":"26","author":"Oen","year":"1996","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jval.2014.08.2668_bib2","first-page":"354","article-title":"What is the impact of adolescent arthritis and rheumatism? Evidence from a national sample of Canadians","volume":"32","author":"Adam","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2014.08.2668_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/art.21689","article-title":"Treatment of pain in juvenile idiopathic arthritis: a survey of pediatric rheumatologists","volume":"55","author":"Kimura","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2014.08.2668_bib4","series-title":"The Use of Biologic Response Modifiers in Polyarticular-Course Juvenile Idiopathic Arthritis: A Health Technology Assessment","author":"Costa","year":"2010"},{"key":"10.1016\/j.jval.2014.08.2668_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.semarthrit.2012.10.006","article-title":"The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review","volume":"42","author":"Ungar","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jval.2014.08.2668_bib6","first-page":"63","article-title":"ACR recommendations for the treatment of JIA: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"2011","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jval.2014.08.2668_bib7","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.120089","article-title":"Access to biologic therapies in Canada for children with juvenile idiopathic arthritis","volume":"39","author":"Leblanc","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2014.08.2668_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/kep347","article-title":"Juvenile idiopathic arthritis: improved outcome requires improved access to care","volume":"49","author":"Foster","year":"2010","journal-title":"Rheumatology"},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2014.08.2668_bib9","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s10198-007-0089-7","article-title":"The burden of rheumatoid arthritis and access to treatment: uptake of new therapies","volume":"8","author":"Jonsson","year":"2008","journal-title":"Eur J Health Econ"},{"issue":"Suppl","key":"10.1016\/j.jval.2014.08.2668_bib10","first-page":"SR1","article-title":"Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries","volume":"17","author":"Orlewska","year":"2011","journal-title":"Med Sci Monit"},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2014.08.2668_bib11","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s10198-007-0086-x","article-title":"Patient access to rheumatoid arthritis treatments","volume":"8","author":"Jonsson","year":"2008","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acr.20337","article-title":"Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs","volume":"63","author":"Ungar","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jval.2014.08.2668_bib13","first-page":"100","article-title":"Public drug plan coverage for children across Canada: a portrait of too many colours","volume":"1","author":"Ungar","year":"2005","journal-title":"Healthc Policy"},{"key":"10.1016\/j.jval.2014.08.2668_bib14","series-title":"Guide to the Methods of Technology Appraisal","year":"2008"},{"key":"10.1016\/j.jval.2014.08.2668_bib15","series-title":"Advances in Health Economics","article-title":"Willingness-to-pay for healthcare","author":"Donaldson","year":"2003"},{"key":"10.1016\/j.jval.2014.08.2668_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2307\/1911129","article-title":"Applied welfare economics with discrete choice models","volume":"49","author":"Small","year":"1981","journal-title":"Econometrica"},{"key":"10.1016\/j.jval.2014.08.2668_bib17","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2012.03.022","article-title":"Parental and societal values for the risks and benefits of childhood combination vaccines","volume":"30","author":"Gidengil","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2014.08.2668_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1399-0004.2009.01193.x","article-title":"Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children","volume":"75","author":"Regier","year":"2009","journal-title":"Clin Genet"},{"key":"10.1016\/j.jval.2014.08.2668_bib19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/pd.1309","article-title":"Rapid prenatal diagnostic testing for Down syndrome only or longer wait for full karyotype: the views of pregnant women","volume":"25","author":"Ryan","year":"2005","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jval.2014.08.2668_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.08.2668_bib21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/acr.21698","article-title":"Parents\u2019 preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment","volume":"64","author":"Burnett","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jval.2014.08.2668_bib22","unstructured":"Kuhfeld WF. Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques, 2010. Available from: http:\/\/support.sas.com\/techsup\/technote\/mr2010.pdf. [Accessed July 22, 2014]."},{"key":"10.1016\/j.jval.2014.08.2668_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hec.1104","article-title":"Deleting \u2018irrational\u2019 responses from discrete choice experiments: a case of investigating or imposing preferences?","volume":"15","author":"Lancsar","year":"2006","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/hec.1369","article-title":"Rationalising the \u2018irrational\u2019: a think aloud study of discrete choice experiment responses","volume":"18","author":"Ryan","year":"2009","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jhealeco.2009.04.004","article-title":"Hypothetical bias, cheap talk, and stated willingness to pay for health care","volume":"28","author":"Ozdemir","year":"2009","journal-title":"J Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib26","series-title":"Frontiers in Econometrics","article-title":"Conditional logit analysis of qualitative choice behavior","author":"McFadden","year":"1974"},{"key":"10.1016\/j.jval.2014.08.2668_bib27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/hec.984","article-title":"Effects coding in discrete choice experiments","volume":"14","author":"Bech","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib28","series-title":"Applied Choice Analysis: A Primer","author":"Hensher","year":"2005"},{"key":"10.1016\/j.jval.2014.08.2668_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<261::AID-HEC262>3.0.CO;2-N","article-title":"Using conjoint analysis to assess women\u2019s preferences for miscarriage management","volume":"6","author":"Ryan","year":"1997","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/ncprheum0458","article-title":"Treatment of chronic pain in pediatric rheumatic disease","volume":"3","author":"Kimura","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.jval.2014.08.2668_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003129","article-title":"Methotrexate for treating juvenile idiopathic arthritis","author":"Takken","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jval.2014.08.2668_bib32","first-page":"1369","article-title":"Functioning and preferences for improvement of health among patients with juvenile idiopathic arthritis in early adulthood using the WHO ICF model","volume":"33","author":"Arkela-Kautiainen","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2014.08.2668_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0897190008322245","article-title":"Pharmacotherapy of juvenile idiopathic arthritis","volume":"22","author":"Bell","year":"2009","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jval.2014.08.2668_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.22463","article-title":"Economic impact of juvenile idiopathic arthritis","volume":"57","author":"Bernatsky","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2014.08.2668_bib35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar2619","article-title":"Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis","volume":"11","author":"Hayward","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jval.2014.08.2668_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hec.1197","article-title":"A comparison of approaches to estimating confidence intervals for willingness to pay measures","volume":"16","author":"Hole","year":"2007","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib37","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/rheumatology\/41.12.1444","article-title":"Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain","volume":"41","author":"Packham","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2014.08.2668_bib38","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/art.24560","article-title":"Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis","volume":"61","author":"Polinski","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"Spec no.","key":"10.1016\/j.jval.2014.08.2668_bib39","first-page":"SP5","article-title":"Value-based insurance design: aligning incentives to bridge the divide between quality improvement and cost containment","volume":"12","author":"Fendrick","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2014.08.2668_bib40","series-title":"Essential Health Benefits: Balancing Coverage and Cost","year":"2011"},{"key":"10.1016\/j.jval.2014.08.2668_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/art.24338","article-title":"Understanding why rheumatoid arthritis patient treatment preferences differ by race","volume":"61","author":"Constantinescu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2014.08.2668_bib42","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/ard.2003.019422","article-title":"Patient preferences for treatment of rheumatoid arthritis","volume":"63","author":"Fraenkel","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2014.08.2668_bib43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.20829","article-title":"Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis","volume":"51","author":"Barron","year":"2004","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jval.2014.08.2668_bib44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.trb.2009.12.012","article-title":"Hypothetical bias, choice experiments and willingness to pay","volume":"44","author":"Hensher","year":"2009","journal-title":"Transp Res"},{"key":"10.1016\/j.jval.2014.08.2668_bib45","series-title":"Economic Valuation with Stated Preference Techniques: A Manual","author":"Bateman","year":"2002"},{"key":"10.1016\/j.jval.2014.08.2668_bib46","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","article-title":"Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide","volume":"26","author":"Lancsar","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.08.2668_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hec.821","article-title":"Modelling non-demanders in choice experiments","volume":"13","author":"Ryan","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hec.1591","article-title":"How does cost matter in health-care discrete-choice experiments?","volume":"20","author":"Johnson","year":"2011","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib49","series-title":"The Adaptive Decision Maker","author":"Payne","year":"1993"},{"key":"10.1016\/j.jval.2014.08.2668_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.socec.2014.02.009","article-title":"Task complexity and response certainty in discrete choice experiments: an application to drug treatments for juvenile idiopathic arthritis","volume":"50","author":"Regier","year":"2014","journal-title":"J Behav Exp Econ"},{"key":"10.1016\/j.jval.2014.08.2668_bib51","series-title":"Average Total Income by Economic Family Types","year":"2011"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514046178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514046178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:20:40Z","timestamp":1538094040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301514046178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1098301514046178"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2014.08.2668","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parents\u2019 Willingness to Pay for Biologic Treatments in Juvenile Idiopathic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2014.08.2668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}